APA (7th ed.) Citation

Kasahara, Y., Saijo, K., Ueta, R., Numakura, R., Sasaki, K., Yoshida, Y., . . . Ishioka, C. (2024). Pretreatment neutrophil–lymphocyte ratio as a prognostic factor in recurrent/metastatic head and neck cancer treated with pembrolizumab. Scientific Reports, 14(1), 1. https://doi.org/10.1038/s41598-024-79130-7

Chicago Style (17th ed.) Citation

Kasahara, Yuki, et al. "Pretreatment Neutrophil–lymphocyte Ratio as a Prognostic Factor in Recurrent/metastatic Head and Neck Cancer Treated with Pembrolizumab." Scientific Reports 14, no. 1 (2024): 1. https://doi.org/10.1038/s41598-024-79130-7.

MLA (9th ed.) Citation

Kasahara, Yuki, et al. "Pretreatment Neutrophil–lymphocyte Ratio as a Prognostic Factor in Recurrent/metastatic Head and Neck Cancer Treated with Pembrolizumab." Scientific Reports, vol. 14, no. 1, 2024, p. 1, https://doi.org/10.1038/s41598-024-79130-7.